Medium-term result of drug-coated balloon with paclitaxel in endovascular treatment of femoropopliteal artery in- stent restenosis
10.3760/cma.j.cn113855-20220314-00152
- VernacularTitle:药物球囊在股腘动脉支架内再狭窄中运用的中期随访结果
- Author:
Xiande YE
1
;
Jingpu ZHU
;
Ximing GONG
;
Qihong NI
;
Yuli WANG
;
Lan ZHANG
;
Meng YE
Author Information
1. 上海浦东新区医院普外科，上海 200120
- Keywords:
Balloon;
Peripheral arterial disease;
In-stent restenosis;
Endovascular treatment
- From:
Chinese Journal of General Surgery
2022;37(11):826-829
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of drug-coated balloon (DCB) with paclitaxel in the treatment of femoropopliteal artery in-stent restenosis.Methods:From Dec 2016 to Jul 2020, clinical and follow-up data of femoropopliteal artery in-stent restenosis (ISR) treated with paclitaxel DCB were retrospectively analyzed.Results:Firty-two patients (56 lower limbs) with femoropopliteal artery ISR underwent DCB therapy. According to Rutherford classification, 1 case was R2 (1.7%), 9 cases were R3 (23.2%), 23 cases were R4 (41.1%), 15 cases were R5 (26.8%) and 4 cases were R6 (7.1%). According to Tosaka classification of ISR, 46 (81.2%)limbs were Tosaka Ⅱ, 10(17.9%)limbs were Tosaka Ⅲ Mean lesion length of ISR was (240±122)mm. Bail-out stent implantation was performed in 25% cases. The median follow-up time was 18 months. The all-cause mortality rate was 11.8%, the major amputation rate was 5.9%, the primary patency rate was 53.4%, the primary assisted patency rate was 67.1%, the secondary patency rate was 93.2%, and the F-TLR was 77.2%.Conclusion:DCB is a safe and effective endovascular therapy for femoropopliteal artery ISR.
